The global phosphodiesterase (PDE) inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The PDE is found in the cytosol, plasma membranes, endoplasmic reticulum, nuclear membranes, and cytoskeleton. Majorly, the two types of PDE inhibitors including the selective and non-selective are being discovered as possible treatments for various indications, such as chronic obstructive pulmonary disease (COPD), Alzheimer’s disease, and other ailments. Thus, such novel application of these inhibitors in the treatment of various diseases is promising a strong market growth during the forecast period. Another pivotal factor that is driving the global PDE inhibitors market growth includes the rise in the prevalence of erectile dysfunction disorder. According to the World Health Organization, about 150 million people have been affected by erectile dysfunction across the globe and the number is projected to reach 230 million by 2025. It is a common medical condition affecting about 15% of men each year.

Some key players operating in the market include Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, and Pfizer Inc., among others. These players are eyeing to strengthen their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in July 2018, Adamis Pharmaceuticals Corp. (Adamis) announced that it has been conducting pre-IND development work for a fast-dissolving sublingual tablet containing tadalafil, which is a drug used to treat erectile dysfunction. Further, in September 2020, Aspargo Laboratories, Inc. acquired the international rights to Sildenafil oral spray for the treatment of erectile dysfunction.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, and Pfizer Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Phosphodiesterase (PDE) Inhibitors Market by Segmentation

By Type 

• Selective PDE Inhibitors

o PDE-1

o PDE-2

o PDE-3

o PDE-4

o PDE-5

o Others

• Non-Selective PDE Inhibitors

By Route of Administration 

• Oral

• Topical

• Others

By Application 

• CVD

• Erectile Dysfunction

• Pulmonary Hypertension

• Respiratory Disease

• Benign Prostate Hyperplasia

• Others

Global Phosphodiesterase (PDE) Inhibitors Market by Region